Preparation method of sialic acid glycan enhanced soybean protein
Sialic acid glycosan-fortified soy protein conjugate was prepared by combining casein glycomegapeptide or hydrolyzed oomomin with soy protein that removes mannan, which solves the intestinal problems caused by high mannose in aquatic feeds. , improves its application value and intestinal health benefits in aquatic feeds.
Patent Information
- Application Number
- CN202411200246.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
The high level of mannose in existing soy protein in aquatic feed causes intestinal fermentation, causing fish and shrimp to float up and die, and lacks sialic acid modifications that function similar to animal-derived proteins, affecting intestinal health.
Combining casein glycomegapeptide or hydrolyzed oomomin with mannan-removing soy protein, sialic acid glycan enhances soy protein conjugates to enhance its digestibility , antioxidant properties and intestinal microbiota regulation function.
The prepared sialic acid glycan-enhancing soy protein conjugates have higher solubility, antioxidant ability and intestinal microbiota regulation effect, significantly inhibit the growth of harmful bacteria, promote the reproduction of probiotics, and improve intestinal health.
Smart Images

Figure CN119054770A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing sialic acid polysaccharide reinforced soybean protein, belonging to the technical field of functional protein production. Background Art
[0002] Sialic acid is a large class of nine-carbon ketose acids. It is an abundant component of vertebrate glycoproteins, glycolipids and milk oligosaccharides, as well as some microbial surface polysaccharides, mediating a variety of functions, including polysaccharide-protein, cell-cell and microbe-host recognition. The most common form of sialic acid in humans is N-acetylneuraminic acid (Neu5Ac). Meat-based foods, poultry eggs or dairy products in the human diet contain more sialic acid. Dietary sialic acid intake is beneficial to the growth of microorganisms with sialic acid metabolism ability in the intestine, which will affect the composition and metabolism of the intestinal microbiota, thereby regulating intestinal immunity and human health. For example, about 57% of N-glycans and most glycolipids in human milk are sialylated glycoconjugates, which may be involved in infant neurodevelopment and cognition. Sialic acid in the adult intestine can also come from the diet. Fruits, vegetables, soybeans and edible fungi do not contain any sialic acid. The content of N-glycolylneuraminic acid (Neu5Gc) is found to be moderately high in mammalian products (red meat such as pork, beef and mutton), while there is no Neu5Gc in poultry, eggs or aquatic products. Neu5Ac may compete with Neu5Gc for integration into cells, where it undergoes metabolism, enters human tissues and triggers interactions with "xenoautoantigen" inflammatory antibodies.
[0003] As a nutrient for intestinal microorganisms, sialic acid can promote the growth of microorganisms capable of sialic acid metabolism, such as Bacteroides fragilis and Akkermansia, and affect intestinal homeostasis. Studies have shown that supplementing with sialic acid glycoproteins or sialylated glycans can change the composition of the entire intestinal microbiota, thereby improving the health of the body, including reducing the risk of colorectal cancer and atherosclerosis. In addition, some sialic acid glycoproteins in the diet, such as egg ovomucin, have biological functions such as antioxidant, remodeling intestinal flora, and regulating immunity. It can be seen that the intake of sialic acid from the diet, especially the bound sialic acid glycans, is particularly important for human intestinal health.
[0004] At present, most vegetarian meat products use soy protein as raw material, and soy protein isolate is also the main component of protein powder nutritional supplements. Studies have found that some soy proteins contain core α1,3-fucosylated N-glycans that may be related to soy allergies, most soy proteins mainly contain high-mannose N-glycans, and some soy proteins are not glycosylated. Protein and carbohydrates are both indispensable nutrients for the human body. Animal-derived proteins generally contain N-glycosylation and O-glycosidation modifications, especially the ends of the sugar chains are mostly sialic acid, which is one of the important differences between plant protein and animal protein; sialic acid in dietary animal-derived proteins also has multiple biological functions, especially in regulating intestinal health.
[0005] In order to enhance the functional properties of soy protein, protein glycosylation modification is generally used to improve its solubility, emulsification, emulsion stability, water retention, gelation, thermal stability, freeze-thaw stability, antigenicity and other functions. A large number of scholars have conducted research on the glycosylation modification of soy protein using neutral monosaccharides, disaccharides, oligosaccharides and polysaccharides (such as dextran, glucose, oligogalactose, etc.), but these studies have not focused on the functional differences between soy protein and animal protein containing sialic acid. A typical case is that aquatic feeds need to add a large amount of fish meal rich in animal protein, while adding too much soy protein is not conducive to the growth of aquatic animals, because the high mannose of soy protein ferments and produces gas in the intestines of aquatic animals, causing fish and shrimp to float and die, while the glycosylation modification contained in animal protein (such as fish meal), especially O-glycans or N-glycans containing sialic acid, can improve the intestinal flora of aquatic animals and inhibit the growth of gas-producing flora.
[0006] Therefore, developing a cheap sialic acid polysaccharide-fortified soy protein with similar functions to animal-derived glycoproteins can enhance the biological functions and nutritional value of soy protein and broaden the application of functional soy protein in health food (such as nutritionally fortified protein powder), artificial plant meat and other industries. In the future, sialic acid polysaccharide-fortified soy protein can also replace fish meal in aquatic feed. Summary of the invention
[0007] In order to solve the above problems, the present invention combines casein glycomacropeptide or hydrolyzed ovomucin with soy protein from which mannan is removed to prepare a conjugate of sialic acid polysaccharide-enhanced soy protein. The conjugate of sialic acid polysaccharide-enhanced soy protein prepared by the present invention has stronger digestion resistance, antioxidant property, solubility and the function of regulating intestinal flora.
[0008] The first object of the present invention is to provide a sialic acid polysaccharide-fortified soybean protein conjugate, wherein the conjugate is prepared from a sialic acid polysaccharide donor and soybean protein from which mannose is removed;
[0009] The sialic acid polysaccharide donor includes casein glycomacropeptide or hydrolyzed ovomucin;
[0010] The method for preparing the soy protein from which mannan is removed comprises:
[0011] The soybean protein is mixed with sodium acetate buffer to obtain a mixed solution; mannanase is added to react; after the reaction is completed, the soybean protein is dialyzed, concentrated, and dried to obtain the soybean protein from which mannan is removed;
[0012] The preparation method of the hydrolyzed ovomucin comprises:
[0013] Using pronase and trypsin in a boric acid buffer to hydrolyze ovomucin in sequence to prepare hydrolyzed ovomucin;
[0014] The preparation method of the sialic acid polysaccharide reinforced soybean protein conjugate comprises:
[0015] The sialic acid polysaccharide donor and soybean protein are mixed, dissolved in water, hydrolyzed with glutaminase, and dried to prepare a sialic acid polysaccharide-reinforced soybean protein conjugate.
[0016] In one embodiment, the amount of mannanase added to the mixed solution is 0.2-0.5 U / mL, and the enzymolysis time is 12-20 hours.
[0017] In one embodiment, the amount of pronase and trypsin in the boric acid buffer is 5 to 10 U / mL, and the enzymatic hydrolysis time is 1 to 3 hours.
[0018] In one embodiment, the mass ratio of the sialic acid glycan donor to the soybean protein is 1:1-3.
[0019] In one embodiment, the amount of glutaminase added is 8 to 12 U / mL, and the enzymatic hydrolysis time is 2 to 4 hours.
[0020] In one embodiment, the concentration of soy protein is 20-50 mg / mL.
[0021] In one embodiment, the molecular weight of the soybean protein is 10 KDa to 100 KDa.
[0022] In one embodiment, the concentration of sodium acetate buffer is 50 mmol / L and the pH is 4.5.
[0023] In one embodiment, the hydrolyzed ovomucin is a hydrolyzed product of frenulum byproducts, and the frenulum byproducts are filtration byproducts produced by one or more processing processes including chicken eggs, duck eggs or goose eggs; optionally, the frenulum byproduct is ovomucin.
[0024] The second object of the present invention is to provide a product, which contains any of the above-mentioned sialic acid polysaccharide-fortified soybean protein conjugates.
[0025] In one embodiment, the product includes food, cosmetics, health products or medicines.
[0026] In one embodiment, the food includes: additives, feed, and nutritional supplements.
[0027] The third object of the present invention is to provide the use of any of the above-mentioned sialic acid polysaccharide-fortified soybean protein conjugates in the preparation of products.
[0028] In one embodiment, the conjugate of sialic acid polysaccharide fortified soybean protein is used to prepare slowly digestible foods, health products for regulating intestinal flora or anti-oxidation, antioxidant cosmetics, and medicines for regulating intestinal flora or anti-oxidation.
[0029] In one embodiment, the product comprises food, cosmetics, health products or medicines.
[0030] In one embodiment, the food includes: additives, feed, nutritional supplements; the additives include emulsifiers, stabilizers, thickeners and the like.
[0031] The fourth object of the present invention is to provide a method for improving the performance of soybean protein, wherein a sialic acid polysaccharide donor is coupled with soybean protein from which mannose is removed to prepare soybean protein with improved performance;
[0032] The properties include: resistance to digestion, antioxidant activity, solubility, and intestinal flora regulation ability;
[0033] The sialic acid polysaccharide donor includes casein glycomacropeptide or hydrolyzed ovomucin;
[0034] The method for preparing the soy protein from which mannan is removed comprises:
[0035] The soybean protein is mixed with sodium acetate buffer to obtain a mixed solution; mannanase is added to react; after the reaction is completed, the soybean protein is dialyzed, concentrated, and dried to obtain the soybean protein from which mannan is removed;
[0036] The preparation method of the hydrolyzed ovomucin comprises:
[0037] Using pronase and trypsin in a boric acid buffer to hydrolyze ovomucin in sequence to prepare hydrolyzed ovomucin;
[0038] The preparation method of the sialic acid polysaccharide reinforced soybean protein conjugate comprises:
[0039] The sialic acid polysaccharide donor and soybean protein are mixed, dissolved in water, hydrolyzed with glutaminase, and dried to prepare a sialic acid polysaccharide-reinforced soybean protein conjugate.
[0040] In one embodiment, the intestinal flora regulating ability is to inhibit the relative abundance of harmful bacteria Escherichia coli-Shigella and increase the relative abundance of beneficial bacteria Bifidobacterium, Lactobacillus, Ruminococcus (Ruminococcus)_torques_group and Clostridium_sensu_stricto_1.
[0041] In one embodiment, the amount of mannanase added to the mixed solution is 0.2-0.5 U / mL, and the enzymolysis time is 12-20 hours.
[0042] In one embodiment, the amount of pronase and trypsin in the boric acid buffer is 5 to 10 U / mL, and the enzymatic hydrolysis time is 1 to 3 hours.
[0043] In one embodiment, the mass ratio of the sialic acid glycan donor to the soybean protein is 1:1-3.
[0044] In one embodiment, the amount of glutaminase added is 8 to 12 U / mL, and the enzymatic hydrolysis time is 2 to 4 hours.
[0045] Beneficial Effects of the Invention
[0046] The present invention combines casein glycomacropeptide or hydrolyzed ovomucin with soy protein from which mannan is removed to prepare a conjugate of sialic acid polysaccharide-enhanced soy protein. The conjugate of sialic acid polysaccharide-enhanced soy protein prepared by the present invention has stronger digestion resistance, antioxidant property, solubility and the function of regulating intestinal flora.
[0047] Specific:
[0048] 1. The solubility of the frenulum-ovomucin peptide-demannosed soybean protein conjugate and the casein glycomacropeptide-demannosed soybean protein conjugate of the present invention is more than 75%;
[0049] 2. The DPPH radical scavenging rates of the 6 mg / mL umbilical cord-ovomucin peptide-demannosed soybean protein conjugate and the casein glycomacropeptide-demannosed soybean protein conjugate of the present invention are 65.04% and 64.02%, respectively, and the hydroxyl radical scavenging rates are 74.91% and 69.30%, respectively, which are significantly better than those of soybean protein, umbilical cord-ovomucin peptide, casein and non-demannosed soybean protein conjugate;
[0050] 3. The frenulum-ovomucin peptide-demannose soybean protein conjugate and casein glycomacropeptide-demannose soybean protein conjugate of the present invention can inhibit digestion rate, and the inhibition rate of gastric and intestinal digestion reaches 83% and 86% or more respectively;
[0051] 4. The ligament-ovomucin peptide-demannose soybean protein conjugate and casein glycomacropeptide-demannose soybean protein conjugate of the present invention can inhibit the relative abundance of harmful bacteria Escherichia coli-Shigella, and increase the relative abundance of beneficial bacteria Bifidobacterium, Lactobacillus, Ruminococcus (Ruminococcus)_torques_group and Clostridium_sensu_stricto_1;
[0052] 5. The sialic acid polysaccharide of the present invention is derived from the ovomucin peptide, which is a by-product of liquid egg processing, is relatively cheap and easy to obtain; while the casein glycomacropeptide is derived from the hydrolyzate of whey casein, which is abundant in source, and the raw materials are all food grade, so the formed product meets the food grade standard and meets the food hygiene and safety requirements. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 This is a solubility test diagram.
[0054] Figure 2 This is an antioxidant test chart.
[0055] Figure 3 This is a gastrointestinal digestibility test chart.
[0056] Figure 4 This is the fermentation pH detection chart.
[0057] Figure 5 This is a detection chart of the level of fecal bacteria fermentation in vitro.
[0058] Figure 6 This is a graph showing the level of detection of the intestinal tract of mice.
[0059] Figure 7 Figure 2 is a heat map of genus-level abundance in the mouse intestine. DETAILED DESCRIPTION
[0060] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explaining the present invention and are not used to limit the present invention.
[0061] Source of raw materials:
[0062] Casein glycomacropeptide was sourced from Arla Foods Ingredients;
[0063] The frenulum-ovomucin was derived from the processing byproduct of Jiangsu Tiancheng Egg Industry Co., Ltd.;
[0064] Pronase was purchased from Shanghai Titan Technology Co., Ltd.; catalog number 100735A;
[0065] Trypsin was purchased from Shanghai Titan Technology Co., Ltd.; catalog number 88927B;
[0066] TG enzyme (glutaminase) was purchased from Xiasheng (Beijing) Biotechnology Development Co., Ltd., catalog number FDG-2210;
[0067] All the above raw materials are food grade.
[0068] Preparation method of frenulum-ovomucin:
[0069] The egg liquid is filtered through a fine mesh of about 50 mesh, and the retained solid part contains the frenulum and part of the ovomucin, which is the frenulum-ovomucin (abbreviated as ovomucin).
[0070] Test method:
[0071] DPPH free radical scavenging ability determination:
[0072] Different concentration gradient sample solutions and equal volume of 0.2mmol·L -1 DPPH solution (dissolved in anhydrous ethanol) was mixed evenly, placed in a dark place to avoid light for 30 minutes, and then the absorbance at 517nm was detected using a multifunctional microplate reader. Ultrapure water was used as a blank control, and VC aqueous solution was used as a positive control.
[0073] DPPH free radical scavenging rate (%) = (1-absorbance of experimental group / absorbance of blank group) × 100% Determination of hydroxyl free radical scavenging ability:
[0074] Different concentration gradient sample solutions were mixed with equal volumes of 9 mmol·L -1 Ferrous sulfate solution and 9mmol·L -1 Mix the hydrogen peroxide solution (prepared immediately before use) evenly and react at 37°C for 10 min. After the reaction is complete, add an equal volume of 9 mmol·L -1 Salicylic acid solution (dissolved in anhydrous ethanol) was reacted again at 37°C for 30 min. The absorbance at 510 nm was then measured using a multifunctional microplate reader. Ultrapure water was used as a blank control, and VC aqueous solution was used as a positive control.
[0075] Hydroxyl free radical scavenging rate (%) = (1-absorbance of experimental group / absorbance of blank group) × 100%;
[0076] Simulated saliva digestion method:
[0077] The saliva digest solution was prepared by dissolving 56.3 mg KCl, 57.2 mg NaHCO3, 6.0 mg NaCl, 8.4 mg CaCl2 and 7500 U α-amylase in 50 mL deionized water. Then, 20 mL of the saliva digest solution was added to 400 mg of casein glycomacropeptide-soy protein conjugate and ligament-ovomucin peptide-soy protein conjugate in tubes I and II, and 20 mL of the saliva digest solution was mixed with 400 mg of soy protein solution in tube III. Tube III was used as a control group. Tubes I, II, and III were incubated in a shaking water bath (50 r / min) at 37°C. Then, after digestion for 15 min, they were boiled at 100°C for 10 min to inactivate α-amylase and stop the reaction.
[0078] Simulated gastric digestion method:
[0079] Artificial gastric juice was mixed with simulated saliva digestion solution in a ratio of 1:1, and the pH value of the resulting solution was adjusted to 2.0 using 0.1 mol / L HCl solution. After digestion at 80 r / min for 2 h, the mixture was shaken in a water bath at 37 °C, and samples were taken and boiled at 100 °C for 10 min.
[0080] Simulated small intestine digestion method:
[0081] The pH value of the gastric digestive fluid obtained above was adjusted to 7.0 with 1 mol / L sodium bicarbonate solution, and then an equal proportion of artificial small intestinal fluid was added thereto. The gastric digestion process was simulated in a 37°C water shaking water bath (50 r / min). After digestion for 4 hours, samples were taken and boiled at 100°C for 10 minutes.
[0082] The protein content of the supernatant at each stage was determined by BCA method, and the gastric protein digestibility and intestinal protein digestibility were calculated.
[0083] Stomach protein digestibility (%) = (A0-A1) / A0×100%;
[0084] Intestinal protein digestibility (%) = (A1-A2) / A1×100%;
[0085] Among them, A0 is the protein content after saliva digestion, A1 is the protein content after 2 hours of gastric digestion, and A2 is the protein content after 4 hours of gastrointestinal digestion each time.
[0086] Example 1: Preparation of casein glycomacropeptide-demannose soybean protein conjugate
[0087] The preparation of casein glycomacropeptide-soy protein conjugate comprises the following steps:
[0088] (1) Weigh 6 g of soybean protein into a 250 mL flask, add 200 mL of 50 mM sodium acetate buffer, mix the solution, and let it stand at room temperature for 20 min to obtain a mixed solution.
[0089] (2) The pH of the mixed solution was adjusted to 4.5, and mannosidase (final concentration was 0.25 U / mL) was added to react at 37°C for 18 h. After the reaction, the mixture was dialyzed in deionized water using a 3000 Da dialysis bag to remove the sodium acetate buffer solution. After the dialysis, the mixture was concentrated by rotary evaporation and freeze-dried (-50°C, vacuum degree 101 kPa) to obtain demannose soybean protein.
[0090] (3) Take 1 g of casein glycomacropeptide and dissolve it in 100 mL of deionized water, add 3 g of demannose soy protein, add 10 U / mL TG enzyme, and react at 37 ° C for 3 h; after the reaction, inactivate at 85 ° C for 10 min, and freeze-dry the reaction solution to obtain casein glycomacropeptide-demannose soy protein conjugate.
[0091] Example 2: Preparation of ovomucin peptide-demannose soybean protein conjugate
[0092] The preparation of the frenulum-ovomucin peptide-soy protein conjugate comprises the following steps:
[0093] (1) Weigh 6 g of soybean protein into a 250 mL flask, add 200 mL of 50 mM sodium acetate buffer, mix the solution, and let it stand at room temperature for 20 min to obtain a mixed solution.
[0094] (2) The pH of the mixed solution was adjusted to 4.5, and mannosidase (final concentration was 0.25 U / mL) was added, and the mixture was reacted at 37°C for 18 h. After the reaction, the mixture was dialyzed in deionized water using a 3000 Da dialysis bag to remove the buffer solution. After the dialysis, the mixture was concentrated by rotary evaporation and freeze-dried to obtain the demannose soy protein.
[0095] (3) Add the ovomucoid byproduct (final concentration reaches 10 g / L) and pronase (final concentration is 7 U / mL) to a 0.1 mol / L boric acid buffer at pH 8.0, and perform a hydrolysis reaction at 39°C and 100 r / min for 2 h. After the reaction is completed, add trypsin (final concentration is 7 U / mL) and react at 37°C and 100 r / min for 2 h. After the reaction is completed, inactivate the enzyme in a boiling water bath for 15 min, cool to room temperature, centrifuge at 8000 r / min for 10 min, and obtain the supernatant. After freeze-drying (-50°C, vacuum degree 101 kPa), the hydrolyzed ovomucoid peptide is obtained.
[0096] (4) Take 1 g of hydrolyzed ovomucoid peptide and dissolve it in 100 mL of deionized water, add 3 g of demannose soy protein, and then add 10 U / mL TG enzyme (based on the total system mass). React at 37°C for 3 h, inactivate at 85°C for 10 min, and lyophilize the reaction solution to obtain a ovomucoid peptide-demannose soy protein conjugate.
[0097] Example 3: Solubility determination
[0098] On the basis of Example 1, step (2) was omitted, and the remaining steps were the same as those in Example 1, to prepare non-demannose-depleted soybean protein and casein glycomacropeptide-non-demannose-depleted soybean protein conjugate;
[0099] On the basis of Example 2, step (2) was omitted, and the remaining steps were the same as those in Example 2 to prepare non-demannosed soybean protein and umbilical cord-ovomucin peptide-non-demannosed soybean protein conjugates.
[0100] Soy protein, demannose soy protein and ovomucin peptide were mixed in different proportions to prepare a solution with a concentration of 10 mg / mL. The solution was centrifuged at 9690 g for 10 min. The protein content in the supernatant was determined by the Coomassie brilliant blue method. The solubility was expressed as the ratio of the protein content in the supernatant to the total protein. The results are shown in Table 1. Figure 1 shown.
[0101] Among them, soy means: soy protein without demannan;
[0102] dsoy:ovm3:1 means demannose soybean protein:ovomucin peptide are cross-linked in a mass ratio of 3:1;
[0103] dsoy:ovm2:1 means demannose soybean protein:ovomucin peptide are cross-linked in a mass ratio of 2:1;
[0104] dsoy:ovm1:1 means demannose soy protein:ovomucin peptide are cross-linked in a mass ratio of 1:1;
[0105] soy:ovm3:1 means that undemannose-degraded soybean protein:ovomucin peptide are cross-linked in a mass ratio of 3:1;
[0106] soy:ovm2:1 means that undemannosed soybean protein:ovomucin peptide are cross-linked in a mass ratio of 2:1;
[0107] soy:ovm1:1 means that the undemannosed soybean protein and ovomucin peptide are cross-linked in a mass ratio of 1:1.
[0108] Solubility is an important prerequisite for protein functional properties. It is a good index for whether a specific protein can be further applied and is directly related to protein emulsification properties, foaming properties and rheological properties. Figure 1 As shown, the results indicate that compared with non-demannosed soybean protein, the solubility of the conjugate of umbilical cord-ovomucin peptide-demannosed soybean protein was significantly improved, with a solubility of more than 75%; the solubility of the conjugate of casein glycomacropeptide-demannosed soybean protein was also detected by the same method, and was more than 75%.
[0109] Example 4: Antioxidant activity assay
[0110] Sialic acid, soybean protein, vitamin C, casein glycomacropeptide-demannosed soybean protein conjugate (prepared in Example 1) and frenulum-ovomucin peptide-demannosed soybean protein conjugate (prepared in Example 2) were respectively prepared into solutions with concentrations of 0, 1, 2, 3, 4, 5, and 6 g / L, and their DPPH and hydroxyl radical scavenging rates were further determined.
[0111] The results are as follows Figure 2 As shown in Table 1, the DPPH radical scavenging rate and hydroxyl radical scavenging rate of casein glycomacropeptide-demannosylation soybean protein conjugate and ligament-ovomucin peptide-demannosylation soybean protein conjugate were higher than those of soybean protein, sialic acid monomer and non-demannosylation soybean protein conjugate at the same concentration, and lower than that of vitamin C, showing better in vitro antioxidant activity.
[0112] Among them, the DPPH radical scavenging rate of 6 mg / mL umbilical cord-ovomucin peptide-demannosed soybean protein conjugate was 65.04%, which was 15%, 660%, 12% and 37% higher than those of soybean protein, umbilical cord-ovomucin peptide, umbilical cord-ovomucin peptide-non-demannosed soybean protein conjugate and sialic acid at the same concentration, respectively; the DPPH radical scavenging rate of 6 mg / mL casein glycomacropeptide-demannosed soybean protein conjugate was 64.02%, which was 12%, 297%, 26.3% and 34% higher than those of soybean protein, casein glycomacropeptide, casein glycomacropeptide-non-demannosed soybean protein conjugate and sialic acid, respectively.
[0113] Among them, the hydroxyl radical scavenging rate of 6 mg / mL umbilical cord-ovomucin peptide-demannosed soybean protein conjugate was 74.91%, which was increased by 54%, 22%, 40% and 277% for larger soybean protein, umbilical cord-ovomucin peptide, umbilical cord-ovomucin peptide-non-demannosed soybean protein conjugate and sialic acid, respectively; the hydroxyl radical scavenging rate of 6 mg / mL casein glycomacropeptide-demannosed soybean protein conjugate was 69.30%, which was increased by 42%, 821%, 61.3% and 14% for larger soybean protein, casein glycomacropeptide, casein glycomacropeptide-non-demannosed soybean protein conjugate and sialic acid, respectively.
[0114] Table 1 Antioxidant capacity test
[0115]
[0116]
[0117] Example 5: In vitro digestibility determination
[0118] The demannose-removed soy protein and casein glycomacropeptide-demannose-removed soy protein conjugate prepared in Example 1, the umbilicus-ovomucin peptide-demannose-removed soy protein conjugate prepared in Example 2, the umbilicus-ovomucin peptide-non-demannose-removed soy protein conjugate and casein glycomacropeptide-non-demannose-removed soy protein conjugate prepared in Example 3 were taken and their in vitro digestibility was detected.
[0119] The results are as follows Figure 3 As shown, compared with demannose soy protein, the digestibility of sialic acid polysaccharide-fortified soy protein (i.e., casein glycomacropeptide-demannose soy protein conjugate and umbilical cord-ovomucin peptide-demannose soy protein conjugate) was inhibited to a certain extent, among which, the gastric digestibility of casein glycomacropeptide-demannose soy protein conjugate (20.45±0.42%) was 29.87% and 19.65% lower than that of demannose soy protein (29.16±0.65%) and casein glycomacropeptide-non-demannose soy protein conjugate (25.45±0.42%), respectively;
[0120] The intestinal digestibility of casein glycomacropeptide-demannosed soy protein conjugate (43.46±0.43%) was 20.78% and 12.13% lower than that of demannosed soy protein (54.86±0.84%) and casein glycomacropeptide-non-demannosed soy protein conjugate (49.46±0.47%), respectively.
[0121] The gastric digestibility of the conjugate of umbilical cord-ovomucin peptide-demannosylated soy protein (23.29±0.35%) was 20.13% and 14.75% lower than that of demannosylated soy protein (29.16±0.65%) and conjugate of umbilical cord-ovomucin peptide-demannosylated soy protein (27.32±0.27), respectively.
[0122] The intestinal digestibility of the umbilical cord-ovomucin peptide-demannosed soy protein conjugate (46.48±0.45%) was 15.28% and 7.42% lower than that of demannans soy protein (54.86±0.84%) and umbilical cord-ovomucin peptide-demannosed soy protein conjugate (50.21±0.14%), respectively.
[0123] It can be seen that the cross-linking of soy protein and sialic acid polysaccharide will increase the spatial resistance of soy protein and gradually destroy the secondary structure of soy protein, which hinders the contact between pepsin and the internal enzyme sites of soy protein, thereby hindering the digestion of protein in the stomach. In addition, the sialic acid sugar chains of sialic acid polysaccharide-fortified soy protein are exposed and have a structure similar to mucin, which hinders the contact between pepsin and the internal enzyme sites of soy protein, inhibits the catalytic action of protease, and potentially hinders the digestion of protein in the stomach. Similar results have been obtained in intestinal digestion.
[0124] Example 5: Fecal bacteria fermentation detection
[0125] The casein glycomacropeptide-demannose soybean protein conjugate (corresponding to the casein glycomacropeptide-soy protein conjugate in the figure) and the ligament-ovomucin peptide-demannose soybean protein conjugate (corresponding to the ligament-ovomucin peptide-soy protein conjugate in the figure) prepared in Example 1 and Example 2 were added to the basic nutrient medium at a concentration of 5 g / L. The fecal slurry was inoculated into the culture medium at a concentration of 10% (w / v) as the original fecal flora.
[0126] The basic nutrient medium was used as the blank group (BLANK), the basic nutrient medium + demannose soybean protein, and the basic nutrient medium + sialic acid were used as the control group, and each group was cultured in three parallel containers at 37°C for 24 hours. 2 mL of fermentation broth samples were collected after 0, 6, 12, and 24 hours of fermentation.
[0127] The pH changes during the fermentation process are shown in Figure 4 As shown, the results indicate that the pH of casein glycomacropeptide-demannosylation soy protein conjugate and ligament-ovomucin peptide-demannosylation soy protein conjugate is lower than that of demannosylation soy protein, which is more conducive to the growth of probiotics such as lactic acid bacteria, thereby inhibiting the reproduction of potential pathogenic bacteria.
[0128] The bacterial flora results at the genus level are as follows Figure 5As shown, the results showed that after 24 hours of in vitro fecal fermentation, the relative abundance of Escherichia coli-Shigella was higher in the blank group and demannose soy protein group, while the relative abundance of Lactobacillus and Clostridium_sensu_stricto_1 was higher in casein glycomacropeptide-demannose soy protein conjugate and ligament-ovomucin peptide-demannose soy protein conjugate.
[0129] Clostridium_sensu_stricto_1 is the document "In Vitro FermentationCharacteristics for Different Ratios of Soluble to Insoluble Dietary Fiber byFresh Fecal Microbiota from Growing Pigs; DOI:10.1021 / acsomega.9b01849" and the document "Dietary Methionine Restriction Improves Gut Health and Alters the PlasmaMetabolomic Profile in Rats by Modulating the Composition of the GutMicrobiota; DOI:10.3390 / ijms25073657" reported beneficial bacteria.
[0130] That is, casein glycomacropeptide-demannosed soybean protein conjugate and ligament-ovomucin peptide-demannosed soybean protein conjugate can inhibit the relative abundance of harmful bacteria Escherichia coli-Shigella and increase the relative abundance of beneficial bacteria Lactobacillus and Clostridium_sensu_stricto_1.
[0131] Example 6: Animal experiment to detect changes in intestinal flora
[0132] Forty male SPF healthy SD rats (22-23 months, 450±10 g) were used to detect the effects of casein glycomacropeptide-soy protein conjugate and frenulum-ovomucin peptide-soy protein conjugate on intestinal flora.
[0133] The experimental animals were randomly divided into 4 groups (10 in each group). During the experiment, all animals were free to eat and drink, the light-dark cycle was 12h, and the temperature (25±2℃) and humidity (45-60%) were controlled. Casein glycomacropeptide, ligament-ovomucin peptide, demannose soy protein, casein glycomacropeptide-demannose soy protein conjugate (corresponding to casein glycomacropeptide-soy protein conjugate in the figure) and ligament-ovomucin peptide-demannose soy protein conjugate (corresponding to ligament-ovomucin peptide-soy protein conjugate in the figure) were respectively prepared into 1 mg / mL concentration solutions, and each rat was gavaged with 2mL per day, and the mice in the control group were treated with an equal amount of normal saline, and the gavage administration lasted for one week.
[0134] Isolate and collect 1-2 pellets of fresh feces from rats and place them in a sterilized 1.5 mL centrifuge tube. Extract the total DNA of the fecal flora and amplify the 16S rDNA gene in different regions (16S V3-V4) using specific primers and barcodes. All PCR reactions were performed with 15 μL Phusion High-Fidelity PCR Master Mix; forward and reverse primers 2 μmol / L, template DNA about 10 ng. Use truseq DNAPCR-Free Sample Preparation to generate sequencing libraries. Study the microbial community by iTag sequencing of the 16S rDNA gene.
[0135] The results of strain classification at the phylum level are as follows Figure 6 The results showed that at the phylum level, compared with the demannose soy protein group, casein glycomacropeptide group, and ligament-ovomucin peptide group, the casein glycomacropeptide-demannose soy protein conjugate group and the ligament-ovomucin peptide-demannose soy protein conjugate group increased the relative abundance of Firmicutes, among which the ligament-ovomucin peptide-demannose soy protein conjugate group had the most significant effect.
[0136] The strain classification results at the genus level are as follows Figure 7As shown in Table 2. The results showed that at the genus level, the casein glycomacropeptide-demannosylation soy protein conjugate group enriched Bifidobacterium, which is a recognized probiotic. The ligament-ovomucin peptide-demannosylation soy protein conjugate enriched Ruminococcus (Ruminococcus_torques_group), which is a beneficial bacterium that can produce butyrate in the human body to exert anti-inflammatory effects (reported in the literature "Gutdysbiosis induced by antibiotics is improved by tangerine pith extract inmice; DOI:10.1016 / j.nutres.2022.01.005"). The casein glycomacropeptide-demannosylation soy protein conjugate and the ligament-ovomucin peptide-demannosylation soy protein conjugate can enrich Clostridium_sensu_stricto_1, which is a fiber-degrading bacterium that can degrade cellulose and hemicellulose by using glucose and is also related to the formation of short-chain fatty acids. In addition, casein glycomacropeptide-demannosylation soybean protein conjugate and ligament-ovomucin peptide-demannosylation soybean protein conjugate showed inhibitory effects on harmful bacteria Escherichia-Shigella.
[0137] Table 2 Abundance at genus level
[0138]
[0139]
[0140] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A conjugate of sialic acid polysaccharide-enhanced soybean protein, characterized in that: The conjugate is prepared from a sialic acid polysaccharide donor and soybean protein from which mannose is removed; The sialic acid polysaccharide donor includes casein glycomacropeptide or hydrolyzed ovomucin; The method for preparing the soy protein from which mannan is removed comprises: The soybean protein is mixed with sodium acetate buffer to obtain a mixed solution; mannanase is added to react; after the reaction is completed, the soybean protein is dialyzed, concentrated, and dried to obtain the soybean protein from which mannan is removed; The preparation method of the hydrolyzed ovomucin comprises: Using pronase and trypsin in a boric acid buffer to hydrolyze ovomucin in sequence to prepare hydrolyzed ovomucin; The preparation method of the sialic acid polysaccharide-fortified soybean protein conjugate comprises: The sialic acid polysaccharide donor and soybean protein are mixed, dissolved in water, hydrolyzed with glutaminase, and dried to prepare a sialic acid polysaccharide-reinforced soybean protein conjugate.
2. The conjugate according to claim 1, characterized in that The amount of mannanase added to the mixed solution is 0.2-0.5 U / mL, and the enzymolysis time is 12-20 hours; the amount of pronase and trypsin in the boric acid buffer is 5-10 U / mL, and the enzymolysis time is 1-3 hours.
3. The conjugate according to claim 1, characterized in that The mass ratio of the sialic acid polysaccharide donor to the soybean protein is 1:1-3.
4. The conjugate according to claim 1, characterized in that The amount of glutaminase added is 8-12 U / mL, and the enzymatic hydrolysis time is 2-4 hours.
5. A product, characterized in that: The product contains the conjugate of sialic acid polysaccharide-enhanced soybean protein according to any one of claims 1 to 4.
6. The product according to claim 6, characterized in that The products include food, cosmetics, health products or medicines.
7. Use of the sialic acid polysaccharide-fortified soybean protein conjugate according to any one of claims 1 to 4 in the preparation of products.
8. The method according to claim 7, characterized in that: Products include food, cosmetics, health products or medicines.
9. A method for improving the performance of soybean protein, characterized in that: The sialic acid polysaccharide donor and the soybean protein from which mannose has been removed are coupled to prepare soybean protein with improved properties; the properties include: digestibility, antioxidant activity, solubility, and intestinal flora regulation ability; The sialic acid polysaccharide donor includes casein glycomacropeptide or hydrolyzed ovomucin; The method for preparing the soy protein from which mannan is removed comprises: The soybean protein is mixed with sodium acetate buffer to obtain a mixed solution; mannanase is added to react; after the reaction is completed, the soybean protein is dialyzed, concentrated, and dried to obtain the soybean protein from which mannan is removed; The preparation method of the hydrolyzed ovomucin comprises: Using pronase and trypsin in a boric acid buffer to hydrolyze ovomucin in sequence to prepare hydrolyzed ovomucin; The preparation method of the sialic acid polysaccharide-fortified soybean protein conjugate comprises: The sialic acid polysaccharide donor and soybean protein are mixed, dissolved in water, hydrolyzed with glutaminase, and dried to prepare a sialic acid polysaccharide-reinforced soybean protein conjugate.
10. The method according to claim 9, characterized in that The amount of mannanase added to the mixed solution is 0.2-0.5 U / mL, and the enzymolysis time is 12-20 hours; The dosage of pronase and trypsin in boric acid buffer is 5-10 U / mL, and the enzymatic hydrolysis time is 1-3 hours; The mass ratio of sialic acid polysaccharide donor to soybean protein is 1:1-3; The amount of glutaminase added is 8-12 U / mL, and the enzymatic hydrolysis time is 2-4 hours.
Citation Information
Cited By
Application of N-acetylneuraminic acid substances to regulation of intestinal flora of mother and child
CN119732506A
